Carprofen—most commonly known by its brand name Rimadyl, but also sold as Novox, Vetprofen, and various generic formulations—is the most widely prescribed non-steroidal anti-inflammatory drug (NSAID) in veterinary medicine. (For a broader overview of what the drug treats and how it is used, see our Rimadyl for dogs guide; this page is the data-anchored side-effects companion.) Approved by the FDA under NADA 141-053 (originally sponsored by Pfizer, now manufactured and distributed by Zoetis), carprofen has been a cornerstone of canine pain management since its approval in 1996. It is indicated for the relief of pain and inflammation associated with osteoarthritis (OA) and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

For millions of dogs, carprofen has successfully restored mobility, relieved chronic arthritis pain, and facilitated post-surgical recovery. However, as with any systemic medication, its use is accompanied by a risk of adverse events. Because of its sheer prescription volume, carprofen is also the single most-reported canine medication in the FDA’s Center for Veterinary Medicine (CVM) adverse-event database.

This guide provides a comprehensive, data-anchored analysis of carprofen side effects. We examine the exact physiological mechanisms of the drug, break down the historical and current adverse-event data from 52,018 deduplicated FDA reports, isolate high-risk patient profiles—including the well-documented hepatic sensitivity in Labrador Retrievers—and outline the mandatory clinical monitoring protocols and emergency indicators that every dog owner and veterinary professional must know.

---

What is Carprofen (Rimadyl) and How Does it Work?

Carprofen is a non-steroidal anti-inflammatory drug belonging to the propionic acid class, which also includes ibuprofen, naproxen, and ketoprofen. In dogs, carprofen exhibits anti-inflammatory, analgesic, and antipyretic (fever-reducing) properties.

The Mechanism of Action: COX-2 Preference

To understand the side effects of carprofen, it is necessary to examine how it acts on the body’s inflammatory pathways. Like all NSAIDs, carprofen works by inhibiting the cyclooxygenase (COX) enzyme, which is responsible for converting arachidonic acid into prostaglandins—the chemical messengers that mediate pain, inflammation, and fever.

The cyclooxygenase enzyme exists in two primary isoforms:

1. COX-1 (Constitutive): This enzyme is present under normal physiological conditions and produces prostaglandins that perform vital house-keeping functions. These include maintaining mucosal blood flow and cytoprotection in the stomach and duodenum, supporting renal blood flow (particularly during periods of hypotension or dehydration), and regulating platelet aggregation.
2. COX-2 (Inducible): This enzyme is upregulated in response to tissue injury, cytokine release, and inflammatory stimuli. Prostaglandins produced by COX-2 are primarily responsible for the localized pain, vasodilation, edema, and inflammatory cascades associated with joint disease or surgical trauma.

Traditional, non-selective NSAIDs (such as aspirin or human ibuprofen) inhibit both COX-1 and COX-2 non-selectively. This results in high rates of gastrointestinal ulceration and renal compromise because the protective COX-1 pathway is suppressed alongside the inflammatory COX-2 pathway.

Carprofen is characterized as a COX-2 preferential NSAID in dogs. While it does not completely spare COX-1, its inhibitory potency is significantly biased toward COX-2. This preferential selectivity provides therapeutic pain relief while offering a wider margin of gastrointestinal and renal safety than older, non-selective compounds. However, because it is preferential rather than strictly selective, COX-1 inhibition still occurs, particularly at the upper limit of the dosing range or in patients with pre-existing risk factors.

Dog-Only Labeling: Why Cats are Excluded

A critical safety boundary for carprofen is its species restriction: carprofen is labeled for oral use in dogs only and must never be administered to cats.

Feline physiology is uniquely sensitive to NSAIDs due to a genetic deficiency in the hepatic enzyme glucuronyltransferase. Cats cannot perform glucuronide conjugation—the primary metabolic pathway used to biotransform and eliminate carprofen and many other drugs from the body. When a cat is exposed to carprofen, the drug's half-life is dramatically prolonged, leading to rapid accumulation in systemic circulation. This accumulation manifests as severe, acute renal failure, gastric perforation, and hemorrhagic gastroenteritis. While injectable carprofen is sometimes used off-label in other jurisdictions as a single, one-time post-operative dose in cats under strict clinical supervision, oral carprofen must remain strictly dog-only in clinical practice.

---

What Do 52,018 FDA Adverse-Event Reports Show?

Because carprofen has been widely used for three decades, it has generated a substantial volume of safety data. To quantify the real-world safety profile of the drug, we performed a reproducible analysis of the FDA/CVM openFDA animal adverse-event database using the local snapshot dated July 5, 2026.

By querying the database for all reports listing "carprofen" as an active ingredient and deduplicating records by their unique adverse-event report number (unique_aer_id_number), we identified 52,018 unique adverse-event reports naming carprofen. This makes carprofen the highest-reported active ingredient among all canine NSAIDs in the FDA registry (the FDA’s raw ingredient index lists 51,388 reports, with the slight difference representing spelling variants and multi-ingredient combinations deduplicated in our analysis).

[!IMPORTANT] Understanding Spontaneous Reporting Limitations Before reviewing the statistical breakdown of these 52,018 reports, it is essential to establish a critical clinical caveat: spontaneous adverse-event reports represent reporting volume, not true clinical incidence. Because these reports are voluntarily submitted by veterinarians and pet owners (or forwarded by manufacturers), they do not represent a controlled study. They cannot prove direct causality in every case, nor do they record the denominator of how many millions of dogs took carprofen safely without an event. Furthermore, because carprofen is the most frequently prescribed canine NSAID, its total report count is naturally higher than newer, less-prescribed alternatives. These numbers must be used to identify patterns of risk, not to conclude that carprofen is intrinsically more dangerous than other options.

Species and Outcome Distribution

The data strongly support the dog-only labeling of the drug, while highlighting the reality of accidental exposure in other species:

• Dogs: 46,860 reports (90.1% of the total dataset)
• Cats: 1,709 reports (primarily reflecting off-label administration or accidental ingestion)
• Humans: 844 reports (primarily reflecting accidental exposures, such as a child swallowing flavored chewable tablets, or self-administration by owners)
• Other or Unspecified Species: roughly 2,605 reports — the large majority (~2,504) are reports in which the species field was not recorded, with the remainder being a small number of accidental exposures in horses, rabbits, and pocket pets

The recorded outcomes across the 52,018 reports demonstrate the spectrum of severity:

• Died: 7,151 reports
• Euthanized: 1,673 reports
• Ongoing (still being treated or resolving at the time of the report): 7,527 reports
• Recovered/Normal: 4,280 reports
• Recovered with Sequelae (lasting effect after recovery): 199 reports
• Outcome Unknown/Not Provided: 3,347 reports

Because a single report can list more than one outcome—and many list none—these categories overlap and do not sum to the total report count. The death and euthanasia reports (7,151 Died plus 1,673 Euthanized = 8,824, about 17% of the dataset) reflect the reality that when severe NSAID toxicity occurs—specifically hepatic rupture, gastric perforation, or acute renal failure—it can be fatal. However, many of these cases involved chronic administration without bloodwork monitoring, concurrent use of contraindicated medications, or massive accidental overdoses.

The Reaction Spectrum

A detailed count of the specific clinical signs (reactions) recorded across the 52,018 deduplicated carprofen reports reveals a clear hierarchy of organ-system sensitivity. The most frequent reactions map directly to the drug’s pharmacological effects on the gastrointestinal tract, liver, and kidneys:

Clinical Reaction	FDA Report Count	Organ System / Category
Vomiting	12,837	Gastrointestinal
Anorexia (Appetite Loss)	9,835	Gastrointestinal / Systemic
Elevated ALT (Alanine Aminotransferase)	8,655	Hepatic (Liver)
Elevated ALP (Alkaline Phosphatase / SAP)	7,622	Hepatic (Liver)
Depression	6,232	Systemic
Accidental Ingestion / Exposure	6,099	Toxicology (Overdose)
Diarrhea	5,207	Gastrointestinal
Elevated Total Bilirubin	4,441	Hepatic (Liver)
Elevated BUN (Blood Urea Nitrogen)	3,584	Renal (Kidney)
Elevated Creatinine	3,122	Renal (Kidney)
Anemia	2,739	Hematologic (occult GI bleeding)
Icterus (Jaundice)	2,728	Hepatic (Liver)
Lethargy	2,625	Systemic
Melena (Black, Tarry Stools)	1,419	Gastrointestinal (Bleeding)

These figures demonstrate that gastrointestinal signs (vomiting, anorexia, diarrhea) are the most common early warnings, while changes in liver enzymes (ALT, ALP, bilirubin) and kidney values (BUN, creatinine) represent the primary clinical pathology signals. Let us examine each of these risk areas in detail.

---

Gastrointestinal Side Effects: The Most Common Risk

The stomach and upper intestines are highly sensitive to COX inhibition. Prostaglandins produced by COX-1 (and to a lesser extent, COX-2) are responsible for maintaining the mucosal barrier that protects the digestive tract from its own gastric acid. Specifically, prostaglandins:

• Stimulate the secretion of bicarbonate and mucus, which neutralize stomach acid at the cell surface.
• Promote mucosal blood flow, which delivers oxygen and nutrients to the rapidly dividing cells of the gut lining.
• Inhibit gastric acid secretion by parietal cells.

When carprofen suppresses these prostaglandins, the mucosal barrier thins, mucosal blood flow decreases, and gastric acid production increases. This can progress from mild irritation to erosion, ulceration, and ultimately, gastrointestinal perforation.

Common Signs vs. Critical Warning Signs

Early gastrointestinal side effects are common and typically occur within the first 3 weeks of starting treatment. Pet owners must monitor their dogs closely for:

• Mild/Common Signs: Decreased appetite, occasional vomiting, or soft stools. If these signs occur, the medication should be suspended, and a veterinarian consulted.
• Severe/Emergency Signs:
  • Hematemesis: Vomiting blood (which may appear bright red or look like "coffee grounds" due to partially digested blood).
  • Melena: Black, tarry, foul-smelling stools, which indicate bleeding in the stomach or upper small intestine.
  • Hematochezia: Bright red blood in the stool, indicating lower intestinal irritation.
  • Acute Abdominal Pain: The dog may adopt a "play bow" position (chest on the floor, rear end in the air) to relieve abdominal pressure, whine, or resist being touched near the belly.
  • Hypovolemic Shock: Pale gums, rapid heart rate, cold extremities, and collapse—signs that suggest a gastric ulcer has perforated, leading to peritonitis and internal bleeding.

If any severe signs are observed, the drug must be stopped immediately, and the dog must be taken to an emergency veterinary clinic.

---

Hepatic Risks: Idiosyncratic Hepatopathy and the Labrador Retriever Connection

One of the most significant safety concerns associated with carprofen is its potential to cause liver damage. Unlike gastrointestinal irritation, which is a predictable extension of the drug's pharmacology, carprofen-induced liver injury is primarily idiosyncratic.

What is Idiosyncratic Hepatopathy?

"Idiosyncratic" means that the reaction is unpredictable, not related to the dose administered, and occurs in a very small fraction of the patient population. Clinical trials and post-marketing surveillance estimate the incidence of idiosyncratic carprofen hepatopathy at approximately 1 in 5,000 dogs (0.02%).

Because the reaction is not dose-dependent, a normal dose can trigger severe liver injury in a sensitive dog, while an overdose might not cause liver damage in a non-sensitive dog. The underlying mechanism is believed to be an immune-mediated hypersensitivity reaction. The liver metabolizes carprofen into reactive intermediates that bind to hepatic proteins, forming "neoantigens." In genetically predisposed dogs, the immune system recognizes these altered proteins as foreign and mounts an attack on the liver cells, causing acute, severe hepatocellular necrosis.

Why Labrador Retrievers are Flagged

The connection between Labrador Retrievers and carprofen liver reactions is a subject of historical concern and clinical significance. When carprofen was first introduced in the late 1990s, a cluster of acute liver failures was reported in Labrador Retrievers. This led to widespread public concern, sometimes summarized by the phrase "Rimadyl killed my dog."

This clinical reality is reflected in the official FDA drug label. Under the Post-Approval Experience (Hepatic) section, the label explicitly states:

"Approximately one-fourth of hepatic reports were in Labrador Retrievers."

Veterinary pharmacologists have investigated whether Labradors possess a specific genetic defect that impairs their metabolism of carprofen. While a definitive genetic marker has not been isolated, the statistical over-representation of the breed remains clear.

However, veterinarians emphasize two key points:

1. It is not exclusive to Labradors: Idiosyncratic liver injury can occur in any breed, including Golden Retrievers, German Shepherds, and mixed-breed dogs.
2. Labradors are not barred from taking it: The breed correlation does not mean carprofen cannot be prescribed to Labradors. Rather, it means that veterinarians must be exceptionally diligent about baseline bloodwork and follow-up monitoring when prescribing the drug to this breed.

Key Hepatic Signs

If a dog is developing a carprofen-induced liver reaction, the signs typically appear within the first 2 to 6 weeks of initiating therapy. Owners should watch for:

• Progressive anorexia (refusal to eat)
• Persistent vomiting and lethargy
• Icterus (Jaundice): Yellowing of the sclera (whites of the eyes), gums, or inner ears, caused by an accumulation of bilirubin in the tissues.
• Dark-colored urine (orange or brown)

In the FDA dataset, elevated ALT (8,655 reports) and elevated ALP (7,622 reports) are the dominant liver markers, often accompanied by elevated total bilirubin (4,441 reports) and clinical icterus (2,728 reports). If ALT rises significantly (e.g., more than 3 to 4 times the upper limit of normal), carprofen must be discontinued immediately. In most cases, if the drug is stopped early and supportive care (intravenous fluids, liver protectants like S-adenosylmethionine [SAMe] and silybin) is initiated, the liver injury is reversible. If administration continues after liver enzymes rise, the condition can progress to fatal hepatic failure.

---

Renal Risks: When the Kidneys Fail

While gastrointestinal and hepatic events are the most common side effects, the kidneys represent another critical target for NSAID toxicity.

In healthy, well-hydrated dogs, prostaglandins play a minimal role in maintaining renal function. However, during periods of decreased blood volume, hypotension, dehydration, or concurrent heart disease, the kidneys rely heavily on prostaglandins (specifically PGE2 and PGI2) to dilate the renal arterioles. This vasodilation maintains adequate renal blood flow and glomerular filtration rate (GFR).

When a dog is given carprofen, the inhibition of these renal prostaglandins prevents arteriole dilation. In a dehydrated or hypotensive dog, this can lead to acute renal vasoconstriction, localized hypoxia in the renal medulla, and acute kidney injury (AKI).

High-Risk Profiles for Renal Side Effects

Several patient factors increase the risk of carprofen-induced kidney damage:

• Dehydration: A dog that is not drinking, has chronic vomiting/diarrhea, or is exercised heavily in hot weather.
• General Anesthesia: Anesthesia frequently causes hypotension (low blood pressure), which reduces renal perfusion. If carprofen is administered before surgery to a dog that becomes hypotensive during the procedure, the risk of acute renal failure rises significantly. Standard practice is to administer carprofen only after the dog has recovered from anesthesia, is hemodynamically stable, and is drinking water.
• Pre-existing Renal Disease: Dogs with subclinical kidney disease (common in senior arthritic dogs) have fewer functioning nephrons and are highly susceptible to NSAID-induced perfusion deficits.
• Concurrent Medications: The use of diuretics (such as furosemide) or ACE inhibitors (such as enalapril or benazepril)—often prescribed for heart disease—disrupts the kidney's auto-regulatory mechanisms, making NSAID use highly dangerous.

Renal Signs to Watch For

Owners should monitor dogs on long-term carprofen for:

• Polydipsia and Polyuria (PD/PU): A sudden, marked increase in water consumption and urination frequency.
• Decreased urine output (oliguria) or complete cessation of urination (anuria) in severe, acute cases.
• Vomiting, lethargy, and a chemical breath odor (uremic breath) caused by the accumulation of nitrogenous waste products (BUN and creatinine) in the blood.

In our openFDA analysis, elevated BUN (3,584 reports) and elevated creatinine (3,122 reports) were prominent renal markers, underscoring the importance of monitoring kidney function.

---

Drug Interactions: The Danger of Mixing Medications

A significant portion of severe carprofen adverse events reported to the FDA involves improper drug combinations. Carprofen must never be administered concurrently with other drugs that affect the gastrointestinal mucosal barrier or renal perfusion.

The Corticosteroid Contraindication: A Critical Error

The most dangerous drug interaction in veterinary medicine is the combination of any NSAID with any corticosteroid (such as prednisone, prednisolone, dexamethasone, or triamcinolone).

Corticosteroids inhibit phospholipase A2, an enzyme upstream of cyclooxygenase in the arachidonic acid cascade. When a steroid and an NSAID are given together, they synergistically block prostaglandin production. This complete blockade leads to rapid, severe gastrointestinal ulceration, hemorrhage, and high rates of gastric perforation.

[!IMPORTANT] The Washout Period If a dog is being switched from a corticosteroid to carprofen (or vice versa), a washout period is mandatory. This period allows the first drug to be cleared from the system and mucosal prostaglandin synthesis to recover before the second drug is introduced.

• Switching from Corticosteroids to Carprofen: A washout period of 5 to 7 days is typically recommended. For long-acting steroid injections (such as methylprednisolone acetate), the washout period must be extended to 3 to 4 weeks.
• Switching between NSAIDs: If switching a dog from carprofen to another NSAID (e.g., meloxicam or galliprant), a washout period of 3 to 5 days is standard practice to prevent cumulative gastrointestinal irritation.

Other Contraindicated Drug Classes

• Other NSAIDs: Administering carprofen alongside aspirin, meloxicam, deracoxib, or firocoxib is contraindicated. It increases the risk of side effects without providing additional pain relief.
• Diuretics and ACE Inhibitors: As detailed in the renal section, combining carprofen with drugs like furosemide, enalapril, or benazepril (often referred to as the "triple whammy" when combined with a diuretic) can cause acute renal failure.
• Nephrotoxic Drugs: Avoid using carprofen concurrently with other potentially nephrotoxic medications, such as aminoglycoside antibiotics (e.g., amikacin or gentamicin).

---

Clinical Monitoring Protocol: The Safety Blueprint

To minimize the risk of idiosyncratic liver injury, renal compromise, and gastrointestinal damage, a structured clinical monitoring protocol is standard of care for any dog prescribed carprofen.

The Clinical Monitoring Workflow

1. Baseline Evaluation: Perform pre-treatment bloodwork (CBC, Chemistry panel with liver/kidney values).
   • If values are abnormal: Investigate underlying issues and evaluate alternative pain management.
   • If values are normal: Initiate carprofen and educate the owner on warning signs.
2. Initial Treatment & Re-check: At 2 to 4 weeks after starting therapy, perform a follow-up blood panel (focused on liver enzymes like ALT/ALP).
   • If liver enzymes are elevated: Discontinue carprofen immediately and initiate supportive hepatic care.
   • If liver enzymes are normal: Continue therapy.
3. Long-Term Maintenance: Re-check bloodwork every 6 months (or every 3 to 4 months for geriatric or higher-risk patients).

---

1. Pre-Treatment Baseline Bloodwork

Before administering the first dose of carprofen, a veterinarian should perform a comprehensive blood panel:

• Complete Blood Count (CBC): To check for pre-existing anemia (which could suggest occult GI bleeding) or platelet abnormalities.
• Chemistry Panel: Specifically evaluating:
  • Liver Enzymes: Alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin.
  • Kidney Values: Blood urea nitrogen (BUN) and creatinine.
  • Total Protein and Albumin: Low albumin levels can increase the concentration of free, active carprofen in the bloodstream, as the drug is highly protein-bound (greater than 99%).

2. The 2-to-4 Week Re-check

Because idiosyncratic liver reactions typically occur within the first 2 to 6 weeks of starting treatment, a follow-up blood panel is highly recommended 2 to 4 weeks after initiating therapy. This re-check is designed to catch subclinical elevations in liver enzymes (ALT and ALP) before the dog shows physical signs of illness.

3. Long-Term Monitoring Cadence

For dogs on chronic carprofen therapy (e.g., senior dogs with osteoarthritis):

• Healthy Adult Dogs: Chemistry panels should be re-checked every 6 months.
• Geriatric Patients or Dogs with Subclinical Kidney/Liver Changes: Re-checks should occur every 3 to 4 months, or as directed by the veterinarian.

---

How Carprofen Compares to Other Pain Medications

When managing a dog with osteoarthritis, carprofen is one of several available options. Understanding how it compares to other medications helps clinicians and owners make informed choices.

Carprofen vs. Other NSAIDs

• Meloxicam (Metacam): Meloxicam is a COX-2 preferential NSAID available in an oral liquid formulation, which allows for precise dosing in small dogs. Its safety profile is similar to carprofen, but the liquid form makes it easier to titrate to the lowest effective dose.
• Deracoxib (Deramaxx): Deracoxib is a highly COX-2 selective NSAID. It is approved for the control of pain and inflammation associated with osteoarthritis and orthopedic surgery. Like carprofen, it carries risks of GI upset, liver, and kidney reactions, but its higher selectivity theoretically offers a slightly improved gastrointestinal safety margin. (See our deracoxib (Deramaxx) for dogs guide.)
• Grapiprant (Galliprant): Grapiprant is a non-coxib, non-steroidal anti-inflammatory drug. Instead of inhibiting the COX enzyme, it acts as a selective antagonist at the EP4 receptor—the specific prostaglandin receptor responsible for osteoarthritis pain. Because it does not block the production of prostaglandins, it does not interfere with the protective COX-1 and COX-2 homeostatic functions. Grapiprant has a significantly lower risk of gastrointestinal ulceration and kidney damage than carprofen, making it an excellent option for dogs with subclinical kidney disease or those sensitive to standard NSAIDs. However, some dogs may find it less effective for severe, acute inflammatory pain. (See our Galliprant for dogs guide.)

Carprofen vs. Librela (Bedinvetmab)

Librela represents a significant advance in canine osteoarthritis management. It is a monthly injectable monoclonal antibody that targets Nerve Growth Factor (NGF)—a key neurosignaling molecule involved in chronic joint pain. (See our Librela for dogs guide.)

• Mechanism: Librela is not an NSAID. It does not inhibit COX enzymes or prostaglandins. Instead, it binds to NGF, preventing it from attaching to receptors on nerve terminals, which reduces pain signaling.
• Metabolism: Monoclonal antibodies are cleared by normal protein catabolic pathways (broken down into amino acids), sparing the liver and kidneys from metabolic stress.
• Safety Profile: Librela does not cause gastrointestinal ulcers, liver damage, or renal vasoconstriction. It is highly safe for dogs with kidney or liver disease who cannot tolerate oral NSAIDs like carprofen.
• Considerations: While Librela is highly effective for chronic arthritis, it is not indicated for acute post-operative pain. Additionally, because it is an injection, it requires monthly clinic visits.

Medication	Class / Mechanism	Administration	Liver/Kidney Risk	GI Ulcer Risk	Best Use Case
Carprofen	COX-2 Preferential NSAID	Oral (Daily)	Moderate (Requires monitoring)	Moderate	Acute post-op pain; general arthritis pain in healthy dogs
Grapiprant	EP4 Receptor Antagonist	Oral (Daily)	Very Low	Low	Arthritic dogs with early kidney changes or mild GI sensitivity
Librela	Anti-NGF Monoclonal Antibody	Injection (Monthly)	None	None	Chronic osteoarthritis, especially in senior dogs with renal/hepatic disease

---

Accidental Overdose and Ingestion Triage

In our analysis of the openFDA database, accidental exposure (ingestion) accounted for 6,099 reports. This high number is directly linked to a product design feature: Rimadyl and generic carprofen are often formulated as beef-flavored chewable tablets.

While these flavored tablets make daily administration easy, they are highly palatable to dogs. If a dog finds a bottle left on a counter or chews through a plastic container, they will often consume the entire supply.

Toxic Doses and Clinical Signs of Overdose

• Therapeutic Dose: The standard therapeutic dose of carprofen is 4.4 mg/kg (2.0 mg/lb) administered orally once daily, or split into two equal doses of 2.2 mg/kg twice daily.
• Toxic Thresholds:
  • GI Irritation/Mild Toxicity: Can occur at doses exceeding 2 to 3 times the therapeutic dose (e.g., >10–12 mg/kg).
  • GI Ulceration and Bleeding: Is a significant risk at doses exceeding 5 to 10 times the therapeutic dose (e.g., >20–40 mg/kg).
  • Acute Renal Failure: Becomes a primary concern at doses exceeding 10 to 20 times the therapeutic dose (e.g., >40–80 mg/kg), particularly if the dog is dehydrated.
  • Central Nervous System (CNS) Signs: Seizures, tremors, coma, and death are risks at massive overdoses exceeding 30 to 40 times the therapeutic dose (e.g., >120–150 mg/kg).

Emergency Triage Steps for Pet Owners

If you suspect your dog has eaten a toxic amount of carprofen:

1. Calculate the Maximum Ingested Dose: Find the bottle, look at the strength (available as 25 mg, 75 mg, or 100 mg tablets), count how many tablets are missing, and multiply this by the tablet strength to find the total milligrams ingested. Divide this by your dog's weight in kilograms.
2. Call for Professional Guidance Immediately: Contact your veterinarian, a local emergency veterinary clinic, or an animal poison control hotline (such as the ASPCA Animal Poison Control Center or Pet Poison Helpline). Have the dog's weight, the drug strength, and the estimated time of ingestion ready.
3. Do Not Induce Vomiting Without Instruction: If the ingestion occurred within the last 2 hours, a veterinarian may instruct you to induce vomiting using fresh 3% hydrogen peroxide (at a dose of 1 ml per pound of body weight, up to a maximum of 45 ml). However, do not do this if the dog is already lethargic, wobbly, or showing signs of neurological compromise, as this can lead to aspiration pneumonia.
4. Seek Veterinary Care: Overdoses require professional medical intervention. Treatment typically includes:
   • Decontamination: Administration of activated charcoal to bind remaining drug in the GI tract.
   • Gastric Protection: Aggressive therapy with proton pump inhibitors (e.g., omeprazole), H2 blockers (e.g., famotidine), and mucosal protectants (e.g., sucralfate).
   • Intravenous Fluid Therapy: Administered for 24 to 72 hours to maintain renal perfusion and assist the kidneys in flushing the drug from the body.
   • Serial Bloodwork: Monitoring kidney values (BUN, creatinine) and liver enzymes over several days.

---

Frequently Asked Questions

Is carprofen safe for long-term use in dogs with arthritis?

Yes, carprofen can be used safely for long-term arthritis management, provided that the dog undergoes baseline bloodwork before starting, receives regular monitoring panels every 6 months, and is kept on the lowest effective dose. Many arthritic dogs take carprofen for years with excellent results and no adverse effects.

Why does the Rimadyl label mention Labradors and liver problems?

During post-marketing surveillance, a statistically higher proportion of acute liver reactions was reported in Labrador Retrievers. This is noted on the label to alert veterinarians to monitor this breed closely. It does not mean Labradors cannot take carprofen, but baseline and periodic bloodwork are critical.

Can cats take carprofen?

No. Cats cannot safely metabolize carprofen due to a genetic deficiency in the liver enzyme glucuronyltransferase. Oral carprofen can cause acute kidney failure, stomach ulcers, and death in cats. Never give a cat carprofen.

Does carprofen require bloodwork monitoring, and how often?

Yes. Baseline bloodwork (CBC and chemistry panel) is required before starting the drug. A re-check panel is recommended 2 to 4 weeks after starting, followed by repeat checks every 6 months for long-term use.

What is the difference between Rimadyl, Novox, and Vetprofen?

They contain the exact same active ingredient: carprofen. Rimadyl is the original brand-name drug developed by Pfizer (now Zoetis). Novox and Vetprofen are generic formulations. They are therapeutically equivalent and carry the same efficacy and safety profiles.

---

Sources

1. DailyMed / FDA National Library of Medicine: Rimadyl (carprofen) Caplets Label (NADA 141-053). Retrieved from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae09baf6-1d34-44b0-b9c9-aa9766cdab14
2. FDA Center for Veterinary Medicine: Freedom of Information (FOI) Summary, NADA 141-053 (Original Approval, October 25, 1996). Retrieved from: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/586
3. Veterinary Information Network (VIN) / Veterinary Partner: Carprofen (Rimadyl). Retrieved from: https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=102894&id=4951499
4. FDA Center for Veterinary Medicine / openFDA: Animal & Veterinary Event API Dataset. Retrieved from: https://api.fda.gov/animalandveterinary/event.json
5. ASPCA Animal Poison Control Center: Canine NSAID Toxicity Guidelines. Retrieved from: https://www.aspcapro.org/poison
6. American Animal Hospital Association (AAHA): 2022 AAHA Pain Management Guidelines for Dogs and Cats. Retrieved from: https://www.aaha.org/for-veterinary-professionals/aaha-guidelines/2022-aaha-pain-management-guidelines/